Related Experiment Videos
Enzyme immunoassay for myelin basic protein in cerebrospinal fluid
F Najeme1, J Julien, S Herblot
1Laboratoire d'Immunologie Moléculaire, Bâtiment 1b-Carreire Nord, Université de Bordeaux II, France.
Abstract:
Myelin basic proteins (MBPs) are a set of proteins making up about 30% of the protein content of the central nervous system myelin. Four human isoforms have been identified. The most abundant is a highly conserved 18.5 kDa polypeptide. For this species, the amino acid sequence homologies between human and monkey or human and chick are 98.2% and 71.1%, respectively. As a consequence, there is a very good immunological cross-reactivity between the mammalian MBP. This protein has been extensively used to induce experimental allergic encephalomyelits (EAE) in numerous animals. The evolution of chronic EAE in animal is similar to that of multiple sclerosis (MS), a demyelinating human pathology, and chronic EAE is considered to be an animal model of MS. In demyelinating pathologies, MBP concentration in the cerebrospinal fluid (CSF) is considered to be a good marker of demyelination. MBP concentration, in biological fluids, is generally determined by radioimmunoassay (RIA). The RIA technique currently used is highly sensitive (0.1-2.5 ng/ml) but has the drawback of requiring the handling of radioactivity and frequent labelling of MBP. So we developed a new enzyme immunoassay (EIA) technique. Our technique has the same sensitivity as RIA, needs only small volumes of CSF (50 microliters) and the enzyme-labelled MBP tracer is stable for at least 12 months.
Insights
A new enzyme immunoassay (EIA) accurately measures myelin basic proteins (MBPs) in cerebrospinal fluid (CSF). This method offers a sensitive, radioactivity-free alternative to radioimmunoassay (RIA) for diagnosing demyelinating diseases like multiple sclerosis (MS).
Area of Science:
- Neuroscience
- Immunology
- Biochemistry
Background:
- Myelin basic proteins (MBPs) are crucial components of central nervous system myelin.
- MBPs are extensively used to model multiple sclerosis (MS) through experimental allergic encephalomyelitis (EAE) in animals.
- MBP concentration in cerebrospinal fluid (CSF) serves as a key biomarker for demyelinating conditions.
Purpose of the Study:
- To develop a novel enzyme immunoassay (EIA) for quantifying MBP levels.
- To provide a sensitive and stable alternative to radioimmunoassay (RIA) for MBP detection.
Main Methods:
- Development of a new enzyme immunoassay (EIA) technique.
- Utilized enzyme-labelled MBP tracer for detection.
- Validated sensitivity and sample volume requirements.
Main Results:
- The developed EIA exhibits comparable sensitivity to RIA (0.1-2.5 ng/ml).
- The EIA requires only small CSF volumes (50 microliters).
- The enzyme-labelled MBP tracer demonstrates stability for over 12 months.
Conclusions:
- The new EIA is a highly sensitive, practical, and stable method for measuring MBP in CSF.
- This assay offers a valuable, radioactivity-free tool for diagnosing and monitoring demyelinating diseases such as MS.